Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. is dated October 14, 2022. The Company is a foreign private issuer based in Tel Aviv, Israel, focused on the development and commercialization of therapeutic candidates and products including Movantik, Talicia, and Aemcolo.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it addresses a significant delay in the finalization of condensed consolidated interim financial statements for the fiscal quarter ended June 30, 2022.
- Financial Reporting Status: Statements for the quarter ended June 30, 2022, are pending finalization.
- Restatement: The Company intends to restate previously issued financial statements for the three months ended March 31, 2022.
- Reason for Delay: An ongoing analysis by the audit committee regarding adjustments between gross and net revenue.
Material Changes and Developments
The primary material change disclosed is the identification of a material weakness in internal controls over financial reporting related to the recognition of certain allowances for deductions. Consequently, investors are advised not to rely on previously issued interim financial statements for the three months ended March 31, 2022.
Additionally, the Company is engaged in discussions with HCR Collateral Management, LLC regarding strategic alternatives to satisfy outstanding obligations under a credit agreement dated February 23, 2020.
Outlook, Management Commentary, and Risks
Management is implementing additional processes and controls to address the identified material weakness. The Company expects to finalize the June 30, 2022, interim statements and complete the restatement as soon as practicable following the audit committee's review.
Strategic Alternatives: Negotiations are progressing with a potential acquirer for the Movantik asset, though there is no assurance a transaction will close.
Risks and Contingencies:
- Failure to close a strategic transaction regarding Movantik.
- Uncertainty surrounding the restatement of financial statements.
- Material weakness in internal controls over financial reporting.
- Standard biopharmaceutical risks including clinical trial outcomes, regulatory approvals, and commercialization challenges.
Investor Verification Checklist
- Verify the timeline for the release of restated financial statements for the quarter ended March 31, 2022.
- Monitor the status of negotiations with the potential acquirer of Movantik.
- Review the specific details of the material weakness in internal controls and the remediation plan.
- Track the outcome of discussions with HCR Collateral Management, LLC regarding debt obligations.